COPD – targeting the use of inhaled corticosteroids

References

[1]  Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2016. Available from: http://www.goldcopd.org/.

[2]  Wilkie M, Finch S, Schembri S. Inhaled corticosteroids for chronic obstructive pulmonary disease – The shifting treatment paradigm. COPD. 2015; 12 582–90.
| Inhaled corticosteroids for chronic obstructive pulmonary disease – The shifting treatment paradigm.Crossref | GoogleScholarGoogle Scholar | 25774769PubMed |

[3]  D'Urzo A, Donohue J, Kardos P, Miravitlles M, Price D. A re-evaluation of the role of inhaled corticosteroid in the managmenet of patinets with chronic obstructive pulmonary diesse. Expert Opin Pharmacother 2015; 16 1845–60.
| A re-evaluation of the role of inhaled corticosteroid in the managmenet of patinets with chronic obstructive pulmonary diesse.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXht1WntLfE&md5=ea0f6282ba9aae5482991e13e9ca521aCAS | 26194213PubMed |

[4]  Yang I, Clarke M, Sim E, Fong K. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7 CD002991
| 22786484PubMed |

[5]  Shen T, Chang P, Lin C, Chen C, Tu C, Hsia T, et al. Risk of periodontal disease in patients with chronic obstructive Pulmonary disease: a nationwide population-based cohort study. Medicine 2015; 94 e2047
| Risk of periodontal disease in patients with chronic obstructive Pulmonary disease: a nationwide population-based cohort study.Crossref | GoogleScholarGoogle Scholar | 26579813PubMed |

[6]  Kerkhof M, Freeman D, Jones R, Chisholm A, Price D. Predicting frequent COPD exacerbations using primary care data. Int J COPD. 2015; 10 2439–50.

[7]  Haughney J, Gruffydd-Jones K, Roberts J, Lee A, Hardwell A, McGarvey L. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J 2014; 43 993–1002.
| The distribution of COPD in UK general practice using the new GOLD classification.Crossref | GoogleScholarGoogle Scholar | 24176990PubMed |

[8]  Montuschi P, Malerba M, Santini G, Miravitlles M. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today 2014; 19 1928–35.
| Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.Crossref | GoogleScholarGoogle Scholar | 25182512PubMed |

[9]  Miravitlles M, Calle M, Soler-Cataluna J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol 2012; 48 86–98.
| Clinical phenotypes of COPD: identification, definition and implications for guidelines.Crossref | GoogleScholarGoogle Scholar | 22196477PubMed |

[10]  Fingleton J, Travers J, Williams M, Charles T, Bowles D, Strik R, et al. Treatment responsiveness of ohenotypes of symptomatic airways obstruction in adults. J Allergy Clin Immunol 2015; 136 601–9.
| Treatment responsiveness of ohenotypes of symptomatic airways obstruction in adults.Crossref | GoogleScholarGoogle Scholar | 25746966PubMed |

[11]  Pascual RM, Peters S. Asthma. Med Clin North Am 2011; 95 1115–24.
| Asthma.Crossref | GoogleScholarGoogle Scholar | 22032430PubMed |

[12]  Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar O, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184 662–71.
| Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.Crossref | GoogleScholarGoogle Scholar | 21680942PubMed |

[13]  Hospers JJ, Schouten J, Weiss S, Rijcken B, Postma D. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 1999; 160 1869–74.
| Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD3c%2Fls1ehtg%3D%3D&md5=2b906f939029da903f8ad558b153c465CAS | 10588599PubMed |

[14]  Horita N, Miyazawa N, Tomaru K, Inoue M, Kaneko T. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: a systematic review and meta-analysis. Respirology 2015; 20 1153–9.
| Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 26235837PubMed |

[15]  Kew KM, Seniukocich A. Inhaled steroids and the risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3 CD010115
| 24615270PubMed |

[16]  Nadeem NJ, Taylor S, Eldridge S. Withdrawal of inhaled corticosteroids and exacerbations of COPD. Respir Res 2011; 12 107
| Withdrawal of inhaled corticosteroids and exacerbations of COPD.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXht1SgtrbM&md5=68aa0a0fd0d59a669c1b485b776188b7CAS | 21838890PubMed |

[17]  Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology. N Engl J Med 2014; 371 1285–94.
| Withdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodology.Crossref | GoogleScholarGoogle Scholar | 25196117PubMed |

[18]  Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest 2015; 148 1177–83.
| Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia.Crossref | GoogleScholarGoogle Scholar | 26110239PubMed |

[19]  Iqbal A, Barnes N, Brooks J. Is blood eosinophil count a predictor of response to bronchodilators in chronic obstructive pulmonary disease? Results from post hoc subgroup analyses. Clin Drug Investig 2015; 35 685–8.
| Is blood eosinophil count a predictor of response to bronchodilators in chronic obstructive pulmonary disease? Results from post hoc subgroup analyses.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXhsVyms7bM&md5=2509e306fcad1993ceba55b52ae0cc45CAS | 26329916PubMed |

[20]  Pavord I, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroids / long-acting β-2 agonist efficacy in COPD. Thorax 2016; 71 118–25.
| Blood eosinophils and inhaled corticosteroids / long-acting β-2 agonist efficacy in COPD.Crossref | GoogleScholarGoogle Scholar | 26585525PubMed |

[21]  Pascoe S, Locantore N, Dransfield M, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3 435–42.
| Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXmsFSgu7g%3D&md5=94d5d19c9fd3d91117f0d0977271d410CAS | 25878028PubMed |

[22]  Clinical pathways, Northern Region. Severe COPD. http://www.healthpointpathways.co.nz/severe-copd/ Accessed Jan 15^th 2016.